Evidence map›Paper›PMID 42244979›Full record

ArticleTheranostics2026

A PSMA-targeted dextran-based conjugate eradicates PSMA-overexpressing prostate tumors while abolishing cabazitaxel toxicity.

Li Yang, Tingchao Liu, Meng Huo, Weiping Jia, Yu Chen, Maoxu Ge, Yan Pan, Jianfei Shi, Xiaohai Li, Si Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li YangNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Tingchao LiuNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Meng HuoNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Weiping JiaNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Yu ChenNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Maoxu GeDepartment of Pharmacy, Qilu Hospital of Shandong University, Jinan 250012, China.
Yan PanNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.
Jianfei ShiDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States.
Xiaohai LiSantolecan Pharmaceuticals LLC, Jupiter 33458, United States.
Si WangSantolecan Pharmaceuticals LLC, Jupiter 33458, United States.
Yikang ShiNational Glycoengineering Research Center, Shandong University, Qingdao 266237, China; Shandong Center of Technology Innovation for Carbohydrate, Shandong University, Qingdao 266237, China; Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, Shandong University, Qingdao 266237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High expression of prostate-specific membrane antigen (PSMA) is observed in advanced prostate cancer, supplying a promising target for precision therapeutic interventions. Despite its efficacy in metastatic castration-resistant disease, cabazitaxel (CTX) is limited by severe systemic toxicity and a narrow therapeutic index, underscoring the urgent demand for tumor-selective delivery systems. Methods: A novel PSMA-targeted dextran-based conjugate, Dextran-CTX-GLA-EuK, was synthesized via click chemistry by conjugating CTX, γ-linolenic acid (GLA), and a Glu-urea-Lys (EuK) PSMA-targeting ligand to bifunctionalized dextran. Critical Results: The conjugate Dextran-CTX-GLA-EuK exhibited favorable physicochemical properties, high water solubility, and strong PSMA-binding affinity. Conclusions: These findings demonstrate that Dextran-CTX-GLA-EuK synergizes active targeting with dextran-based delivery, enhancing antitumor efficacy while abolishing dose-limiting toxicities. This strategy offers a clinically translatable approach for PSMA-directed therapy in prostate cancer.

Indexed as

Antigens, SurfaceAntineoplastic AgentsDextransGlutamate Carboxypeptidase IIProstatic NeoplasmsTaxoidsAnimalsCell Line, TumorHumansMaleMiceTissue DistributionXenograft Model Antitumor AssaysAntigens, SurfaceAntineoplastic AgentscabazitaxelDextransFOLH1 protein, humanGlutamate Carboxypeptidase IITaxoidscabazitaxeldextrangamma-linolenic acidprostate cancerprostate-specific membrane antigen

Identifiers

PMID42244979
PMCPMC13232434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.